# US 2020/0390749 A1 · Pharmaceutical combinations for use in the treatment of neoplastic diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390749 A1
- Document ID: US20200390749A1
- Status: Published application
- Kind: A1
- Application number: 16/763,099
- Filed: 2018-11-20
- Published: 2020-12-17
- Earliest claimed: 2017-11-20
- Assignees: Basilea Pharmaceutica International AG
- Applicants: Basilea Pharmaceutica International AG
- Inventors: Felix BACHMANN; Heidi LANE; Paul MCSHEEHY
- Web page: https://patentgrep.com/patent/US20200390749A1

## CPC

- A61K 31/4245: Oxadiazoles
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/357: having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides pharmaceutical combinations comprising (a) a compound of formula (I) wherein R represents phenyl or pyridinyl; wherein phenyl is optionally substituted by one or two substituents independently selected from lower alkyl, lower alkoxy, hydroxyl, amino, lower alkylamino, lower dialkylamino, acetylamino, halogen and nitro; and wherein pyridinyl is optionally substituted by amino or halogen; R1 represents hydrogen or cyano-lower alkyl; and wherein the prefix lower denotes a radical having up to and including a maximum of 4 carbon atoms; or a pharmaceutically acceptable derivative thereof; and (b) a compound of Formula (II) (eribulin) or a pharmaceutically acceptable salt thereof and the use of the pharmaceutical combinations in the treatment of neoplastic diseases.

## Claims

### Claim 1

A pharmaceutical combination comprising (a) a compound of formula I
wherein
R represents phenyl or pyridinyl;
wherein phenyl is optionally substituted by one or two substituents independently selected from lower alkyl, lower alkoxy, hydroxyl, amino, lower alkylamino, lower dialkylamino, acetylamino, halogen and nitro;
and wherein pyridinyl is optionally substituted by amino or halogen;
R1 represents hydrogen or cyano-lower alkyl;
and wherein the prefix lower denotes a radical having up to and including a maximum of 4 carbon atoms; or a pharmaceutically acceptable derivative thereof;
and (b) a compound of formula II (eribulin)
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The pharmaceutical combination according to claim 1, wherein the compound of formula I or pharmaceutically acceptable derivative thereof is a compound of formula I-A
or a pharmaceutically acceptable salt thereof, or a compound of formula I-B
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 2)

The pharmaceutical combination according to claim 2, wherein the compound of formula I or pharmaceutically acceptable derivative thereof is the dihydrochloride salt of the compound of formula I-B and wherein the compound of formula II or a pharmaceutically acceptable salt thereof is eribulin mesylate.

### Claim 4 (depends on 1)

The pharmaceutical combination according to claim 1, wherein the mole ratio of the mole amount of the compound of formula I or pharmaceutically acceptable derivative thereof to the mole amount of the compound of formula II or pharmaceutically acceptable salt thereof is 1:1 to 800:1.

### Claim 5 (depends on 1)

A method for treating a neoplastic disease in a subject, comprising the step of administering a pharmaceutical combination according to claim 1 to said subject in need thereof.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the compound of formula I or pharmaceutically acceptable derivative thereof and of the compound of formula II or pharmaceutically acceptable salt thereof are administered to the subject according to cyclic treatment schedules;
wherein when the treatment cycles are of the same duration the mole ratio of the total mole amount of the doses of the compound of formula I or pharmaceutically acceptable derivative thereof to the total mole amount of the doses of the compound of formula II or pharmaceutically acceptable salt thereof administered to the subject over the respective treatment cycles is 1:1 to 800:1;
and wherein when the treatment cycles are of different duration the ratio of the total mole amount of the doses of the compound of formula I or pharmaceutically acceptable derivative thereof to the total mole amount of the doses of the compound of formula II or pharmaceutically acceptable salt thereof administered to the subject over a theoretical period of time corresponding to a common multiple of the duration of the respective treatment cycles is 1:1 to 800:1.

### Claim 7 (depends on 5)

The method according to claim 5, wherein the compound of formula I or pharmaceutically acceptable derivative thereof is administered to the subject according to a continuous treatment schedule and the compound of formula II or pharmaceutically acceptable salt thereof is administered to the subject according to a cyclic treatment schedule and wherein the mole ratio of the total mole amount of the doses of the compound of formula I or pharmaceutically acceptable derivative thereof administered to the subject over a period of the same duration of the treatment cycle of the compound of formula II or pharmaceutically acceptable salt thereof to the total mole amount of the doses of the compound of formula II or pharmaceutically acceptable salt thereof administered to the subject over the treatment cycle is 1:1 to 800:1.

### Claim 8 (depends on 5)

The method according to claim 5, wherein the compound of formula I or pharmaceutically acceptable derivative thereof is administered orally at dose corresponding to the mole equivalent of about 2 mg to about 30 mg of the dihydrochloride salt of the compound of formula I-B per day on days when administered, and wherein the compound of formula II or pharmaceutically acceptable salt thereof is administered intravenously at a dose corresponding to the mole equivalent of eribulin mesylate of about 0.1 mg/m2 to about 2 mg/m2 per week during weeks when administered.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the compound of formula I or pharmaceutically acceptable derivative thereof is administered to the subject at least once per day, and wherein the compound of formula II or pharmaceutically acceptable salt thereof is administered to the subject according to a 21-day treatment cycle with administration initiated on days 1 and 8, or according to a 28-day treatment cycle with administration initiated on days 1 and 15.

### Claim 10 (depends on 5)

The method according to claim 5, wherein the compound of formula I or pharmaceutically acceptable derivative thereof is administered intravenously at a dose corresponding to the mole equivalent of about 15 mg/m2 to about 160 mg/m2 of the dihydrochloride salt of the compound of formula I-B per week during weeks when administered, and wherein the compound of formula II or pharmaceutically acceptable salt thereof is administered intravenously at a dose corresponding to the mole equivalent of eribulin mesylate of about 0.1 mg/m2 to about 2 mg/m2 per week during weeks when administered.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the compound of formula I or pharmaceutically acceptable derivative thereof is administered according to a 21-day treatment cycle with administration initiated on days 1 and 8, or a 28-day treatment cycle with administration initiated on days 1, 8 and 15, and wherein the compound of formula II or pharmaceutically acceptable salt thereof is administered according to a 21-day treatment cycle with administration initiated on days 1 and 8, or according to a 28-day treatment cycle with administration initiated on days 1 and 15.

### Claim 12 (depends on 5)

The method according to claim 5, wherein the neoplastic disease is selected from the group consisting of epithelial neoplasms, squamous cell neoplasms, basal cell neoplasms, transitional cell papillomas and carcinomas, adenomas and adenocarcinomas, adnexal and skin appendage neoplasms, mucoepidermoid neoplasms, cystic neoplasms, mucinous and serous neoplasms, ducal-, lobular and medullary neoplasms, acinar cell neoplasms, complex epithelial neoplasms, specialized gonadal neoplasms, paragangliomas and glomus tumours, naevi and melanomas, soft tissue tumours and sarcomas, fibromatous neoplasms, myxomatous neoplasms, lipomatous neoplasms, myomatous neoplasms, complex mixed and stromal neoplasms, fibroepithelial neoplasms, synovial like neoplasms, mesothelial neoplasms, germ cell neoplasms, trophoblastic neoplasms, mesonephromas, blood vessel tumours, lymphatic vessel tumours, osseous and chondromatous neoplasms, giant cell tumours, miscellaneous bone tumours, odontogenic tumours, gliomas, neuroepitheliomatous neoplasms, meningiomas, nerve sheath tumours, granular cell tumours and alveolar soft part sarcomas, Hodgkin's and non-Hodgkin's lymphomas, other lymphoreticular neoplasms, plasma cell tumours, mast cell tumours, immunoproliferative diseases, leukemias, myeloproliferative disorders, lymphoproliferative disorders and myelodysplastic syndromes.

### Claim 13 (depends on 5)

The method according to claim 5, wherein the neoplastic disease is a cancer.

### Claim at position 14

14-15. (canceled)

### Claim 16 (depends on 5)

The method according to claim 5, wherein the subject is human.

### Claim 17 (depends on 13)

The method according to claim 13, wherein the cancer is breast cancer.
